# Peri-operative SLOG for Localized Pancreatic Cancer

> **NCT05048524** · PHASE2 · UNKNOWN · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 64 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Pancreas Cancer

## Interventions

- **DRUG:** S-1, leucovorin, oxaliplatin and gemcitabine

## Key facts

- **NCT ID:** NCT05048524
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-03
- **Primary completion:** 2024-08-24
- **Final completion:** 2025-08-24
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048524, "Peri-operative SLOG for Localized Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05048524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*